{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T04:20:35Z","timestamp":1791778835732,"version":"4.3.4"},"reference-count":41,"publisher":"Wiley","issue":"14","license":[{"start":{"date-parts":[[2011,12,16]],"date-time":"2011-12-16T00:00:00Z","timestamp":1323993600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2012,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>Although convincing data exist regarding the prognostic utility of positron emission tomographic (PET)\u2010computed tomographic (CT) imaging in Hodgkin lymphoma and diffuse large B\u2010cell lymphoma, its prognostic utility both during treatment and immediately after treatment have not been systematically evaluated in a large mantle cell lymphoma (MCL) patient cohort to support its use in clinical practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>The authors conducted a retrospective cohort study to examine the prognostic utility of PET\u2010CT imaging in a uniform MCL patient cohort undergoing dose\u2010intensive chemotherapy (R\u2010HyCVAD) in the frontline setting. The primary study endpoints were progression\u2010free survival (PFS) and overall survival (OS). PET\u2010CT images were centrally reviewed for the purposes of this study using standardized response criteria.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>Fifty\u2010three patients with advanced stage MCL with PET\u2010CT data were identified. With median follow\u2010up of 32 months, 3\u2010year PFS and OS estimates were 76% (95% confidence interval [CI], 64%\u201084%) and 84% (95% CI, 72%\u201090%), respectively. Interim PET\u2010CT status was not associated with PFS (hazard ratio [HR], 0.9; 95% CI, 0.3\u20102.7; <jats:italic>P<\/jats:italic> = .8) or OS (HR, 0.6; 95% CI, 0.1\u20102.9; <jats:italic>P<\/jats:italic> = .5). Post\u2010treatment PET\u2010CT status was statistically significantly associated with PFS (HR, 5.2; 95% CI, 2.0\u201013.6; <jats:italic>P<\/jats:italic> = .001) and trended toward significant for OS (HR, 2.8; 95% CI, 0.8\u20109.6; <jats:italic>P<\/jats:italic> = .07).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>These data do not support the prognostic utility of PET\u2010CT in pretreatment and interim treatment settings. A positive PET\u2010CT after the completion of therapy identifies a patient subset with an inferior PFS and a trend toward inferior OS. Cancer 2012;3565\u20133570. \u00a9 2011 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.26731","type":"journal-article","created":{"date-parts":[[2011,12,16]],"date-time":"2011-12-16T11:07:01Z","timestamp":1324033621000},"page":"3565-3570","source":"Crossref","is-referenced-by-count":44,"title":["Post\u2010treatment (not interim) positron emission tomography\u2010computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R\u2010HyperCVAD"],"prefix":"10.1002","volume":"118","author":[{"given":"Anthony R.","family":"Mato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Svoboda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Zielonka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Agress","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Panush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Toth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Lizotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunita","family":"Nasta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emeline","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L.","family":"Pecora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Goy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,12,16]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"425","article-title":"Rituximab and DHAP followed by intensive therapy with autologous stem\u2010cell transplantation as first\u2010line therapy for mantle cell lymphoma","volume":"91","author":"de Guibert S","year":"2006","journal-title":"Haematologica."},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-147025"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-179739"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.12.3803"},{"key":"e_1_2_6_6_2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1182\/blood.V114.22.403.403","article-title":"R\u2010CHOP, followed by high dose therapy and autologous stem cell rescue (HDT\/ASCR), and R\u2010HyperCVAD have equivalent progression\u2010free survival and are superior to R\u2010CHOP alone in younger patients with mantle cell lymphoma: a comparative effectiveness analysis from the National Comprehensive Cancer Network (NCCN) Non\u2010Hodgkin's Lymphoma Outcomes Database Project [abstract]","volume":"114","author":"LaCasce A","year":"2009","journal-title":"Blood."},{"key":"e_1_2_6_7_2","first-page":"1275","article-title":"Sequential chemotherapy regimens followed by high\u2010dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study","volume":"89","author":"Lefrere F","year":"2004","journal-title":"Haematologica."},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh069"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.1825"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428190009053541"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07498.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22093"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08228.x"},{"issue":"15","key":"e_1_2_6_14_2","doi-asserted-by":"crossref","first-page":"8067","DOI":"10.1200\/jco.2010.28.15_suppl.8067","article-title":"Effect of front\u2010line therapy with either high\u2010dose therapy and autologous stem cell rescue (HDT\/ASCR) or dose\u2010intensive therapy (R\u2010Hypercvad) on outcome in mantle cell lymphoma (MCL) [abstract]","volume":"28","author":"Feldman T","year":"2010","journal-title":"J Clin Oncol."},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-095331"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-236570"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-05-155507"},{"issue":"15","key":"e_1_2_6_18_2","doi-asserted-by":"crossref","first-page":"8092","DOI":"10.1200\/jco.2010.28.15_suppl.8092","article-title":"The association between the Mantle Cell Lymphoma International Prognostic Index (MIPI) and survival in patients treated with rituximab\u2010HCVAD (RHCVAD) alternating with rituximab\u2010methotrexate\u2010AraC (R\u2010MTX\u2010AraC) [abstract]","volume":"28","author":"Mato AR","year":"2010","journal-title":"J Clin Oncol."},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.2305"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008357126404"},{"key":"e_1_2_6_21_2","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1182\/blood.V114.22.3692.3692","article-title":"Interim and end\u2010of\u2010treatment 18F\u2010FDG\u2010PET evaluation of patients with diffuse large B\u2010cell lymphoma (DLBCL) treated with 6 cycles of dose\u2010dense R\u2010CHOP\u201014 immunochemotherapy plus pegfilgrastim for first\u2010line treatment: an open\u2010label clinical trial in Spain [abstract]","volume":"114","author":"Gonzalez\u2010Barca E","year":"2009","journal-title":"Blood."},{"key":"e_1_2_6_22_2","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1182\/blood.V116.21.2793.2793","article-title":"Predictive value for event\u2010free survival of interim 18F\u2010FDG\u2010PET in patients with diffuse large B\u2010cell lymphoma (DLBCL) treated with 6 cycles of dose\u2010dense R\u2010CHOP\u201014 immunochemotherapy plus pegfilgrastim as first\u2010line treatment: an open\u2010label clinical trial In Spain [abstract]","volume":"116","author":"Gonzalez\u2010Barca E","year":"2010","journal-title":"Blood."},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2252"},{"key":"e_1_2_6_24_2","first-page":"613","article-title":"Persistent tumor 18F\u2010FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non\u2010Hodgkin's lymphoma","volume":"85","author":"Jerusalem G","year":"2000","journal-title":"Haematologica."},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2008.n.037"},{"key":"e_1_2_6_26_2","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.1182\/blood.V114.22.4995.4995","article-title":"Response assessment after induction therapy in diffuse large B cell lymphoma (DLBCL): role of fluorodeoxyglucose\u2010positron emission tomography (FDG\u2010PET) in comparison with computed tomography (CT) [abstract]","volume":"114","author":"Puccini B","year":"2009","journal-title":"Blood."},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.10.2930"},{"issue":"15","key":"e_1_2_6_28_2","doi-asserted-by":"crossref","first-page":"8004","DOI":"10.1200\/jco.2010.28.15_suppl.8004","article-title":"Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy","volume":"28","author":"Salles GA","year":"2010","journal-title":"J Clin Oncol."},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_6_30_2","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1182\/blood.V114.22.1402.1402","article-title":"Comparison of contrast\u2010enhanced CT, PET\/CT, PET, and low\u2010dose non\u2010contrast enhanced CT imaging of diffuse large B\u2010cell, follicular, small lymphocytic\/CLL, and marginal zone lymphomas [abstract]","volume":"114","author":"Chong EA","year":"2009","journal-title":"Blood."},{"key":"e_1_2_6_31_2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1182\/blood.V114.22.99.99","article-title":"Interim 18\u2010FDG\u2010positron emission tomography\/computed tomography (PET) failed to predict different outcome in diffuse large B\u2010cell lymphoma (DLBCL) patients treated with rituximab\u2010CHOP [abstract]","volume":"114","author":"Pregno P","year":"2009","journal-title":"Blood."},{"key":"e_1_2_6_32_2","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1182\/blood.V110.11.787.787","article-title":"Limited\u2010stage diffuse large B\u2010cell lymphoma (DLBCL) patients with a negative PET scan following three cycles of R\u2010CHOP can be effectively treated with abbreviated chemoimmunotherapy alone [abstract]","volume":"110","author":"Sehn LH","year":"2007","journal-title":"Blood."},{"key":"e_1_2_6_33_2","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1182\/blood.V114.22.881.881","article-title":"Independent predictive value of PET\u2010CT pre transplant in relapsed and refractory patients with CD20 diffuse large B\u2010cell lymphoma (DLBCL) included in the CORAL study [abstract]","volume":"114","author":"Trneny M","year":"2009","journal-title":"Blood."},{"key":"e_1_2_6_34_2","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1182\/blood.V116.21.2819.2819","article-title":"The outcome of patients with diffuse large B\u2010cell lymphoma (DLBCL) treated with rituximab\u2010CHOP (R\u2010CHOP) is not predicted by 18\u2010FDG\u2010positron emission tomography\/computerized tomography (PET) performed at intermediate in\u2010course evaluation, but only by PET assessed at the end of therapy [abstract]","volume":"116","author":"Vitolo U","year":"2010","journal-title":"Blood."},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-010-1469-2"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802216707"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802311433"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2008.n.019"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/MNM.0b013e32832e0c13"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802382780"},{"key":"e_1_2_6_41_2","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1182\/blood.V114.22.1226.1226","article-title":"Prognostic significance of positron emission tomography (FDG\u2010PET) at baseline and after 4 cycles of R\u2010CHOP in 75 patients with mantle cell lymphoma treated with intensive chemotherapy and autologous stem cell rescue [abstract]","volume":"114","author":"Schaffel R","year":"2009","journal-title":"Blood."},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22807"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.26731","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.26731","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T14:52:16Z","timestamp":1760280736000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.26731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,16]]},"references-count":41,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2012,7,15]]}},"alternative-id":["10.1002\/cncr.26731"],"URL":"https:\/\/doi.org\/10.1002\/cncr.26731","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,16]]}}}